Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TriSalus Life Sciences (TLSIW) Research & Development (2022 - 2025)

TriSalus Life Sciences' Research & Development history spans 4 years, with the latest figure at $2.6 million for Q4 2025.

  • For Q4 2025, Research & Development fell 13.15% year-over-year to $2.6 million; the TTM value through Dec 2025 reached $15.0 million, down 15.39%, while the annual FY2025 figure was $15.0 million, 15.39% down from the prior year.
  • Research & Development reached $2.6 million in Q4 2025 per TLSIW's latest filing, down from $5.2 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $9.5 million in Q3 2023 to a low of $2.6 million in Q4 2025.
  • Average Research & Development over 4 years is $5.3 million, with a median of $5.0 million recorded in 2022.
  • Peak YoY movement for Research & Development: surged 97.71% in 2023, then plummeted 61.91% in 2024.
  • A 4-year view of Research & Development shows it stood at $6.3 million in 2022, then grew by 23.97% to $7.8 million in 2023, then tumbled by 61.91% to $3.0 million in 2024, then dropped by 13.15% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Research & Development are $2.6 million (Q4 2025), $5.2 million (Q3 2025), and $3.9 million (Q2 2025).